Kosh Agarwal
0000-0002-4754-828X
405 papers found
Refreshing results…
What is predicting post-pregnancy ALT flares?
Understanding the Patient Journey Through Education and Consent in Liver Transplantation
Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)
Transient renal dysfunction during INF-free therapy in decompensated HCV cirrhosis patients
Sustained virologic response rates in HCV genotype 1-infected patients treated for 8 weeks with ombitasvir/paritaprevir/r and dasabuvir with ribavirin
Treatment of acute hepatitis C with a pegylated interferon-sparing regimen
Ombitasvir/Paritaprevir/r and Dasabuvir with or without Ribavirin for HCV Patients with Post-Transplant Recurrence
NGAL can act as a renal safety biomarker during long-term antiviral therapy with nucleos(t)ide analogue in chronic hepatitis B
Significant non-adherence to DAA HCV therapy in decompensated patients - a tertiary hepatology centre assessment
HIV and hepatitis delta - the last challenge in the viral hepatitides?
Hepatocellular carcinoma (HCC) surveillance in HIV plus HBV patients: Does a dedicated HIV liver clinic make a difference?
Health resource usage in peri-transplant patients during 12 weeks of therapy with sofosbuvir (SOF), with or without ribavirin (RBV) and an NS5A inhibitor
Bone toxicity during long-term nucleos(t)ide analogues therapy in chronic hepatitis B - is there a relationship between markers of bone toxicity and renal tubular dysfunction ?
Pre-core region mutations analysis helps to delineate immune stage in HBeAg plus children with chronic hepatitis B
Interferon Signaling and the Innate Immune Response: Still Relevant in the Age of Interferon Free Treatment
A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Naive and Experienced Genotype 1, 2, 4, 5, 6 HCV Infected Patients with and without cirrhosis: Results of the ASTRAL-1 Study
Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2)
Differences in NK phenotype in Responders and Relapsers to Directly Acting Antivirals for HCV Infection
Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study
Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
Missing publications? Search for publications with a matching author name.